Company Overview - Kintara Therapeutics completed a private placement with approximately $25 million in gross proceeds on August 31, 2020 [4] - The company has two Phase 3-ready therapeutics: VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC) [4] - The total market opportunity is estimated to be over $1 billion for GBM (>$800 million) and CMBC (~$500 million) [4] VAL-083 (GBM) - The GBM market is projected to grow from $800 million in 2020 to $1.4 billion in 2027 [9] - Median progression-free survival (PFS) in a newly diagnosed trial arm was 8.7 months (CI 6.0-12.0) [10] - 72 out of a planned 83 patients have been enrolled in the recurrent trial arm [11] REM-001 (CMBC) - The market opportunity for CMBC is approximately $500 million [4, 19] - Prior Phase 2/3 clinical trials showed an 80% complete response rate in evaluable lesions across 149 patients [17, 19] - Approximately $7 million is allocated for manufacturing and a 15-patient lead-in study [19] Additional Information - Each molecule has a safety database of approximately 1,100 patients [5, 27]
Kintara Therapeutics (KTRA) Investor Presentation - Slideshow